SPRY Filings — Ars Pharmaceuticals, Inc. - FilingSpy
SPRY
Ars Pharmaceuticals, Inc.
A maker of neffy, the first FDA-approved needle-free nasal spray for emergency treatment of severe allergic reactions (anaphylaxis), replacing the familiar auto-injector shot. Founded in 2015 by Richard Lowenthal, Dr. Sarina Tanimoto, and Dr. Robert Bell, the company's name is understood to reflect its focus on the allergic reaction system. neffy marked the first significant innovation in epinephrine delivery in over 35 years, offering a needle-free option for people who fear or avoid injectors.
Neffy U.S. product revenue more than doubled year over year to $26.2M, but SG&A rose 43% to $77.6M, driving a $62.3M net loss.
Neffy's U.S. market share doubled to 5%, but the cost of getting there continued to outrun the . Total revenue rose 114% to $33.7 million, driven by a 105% increase in U.S. neffy net product revenue to $26.2 million, while selling, general and administrative expenses climbed 43% to $77.6 million, pushing the net loss to $62.3 million. Cash fell to $143.8 million, and the company is now drawing on debt to reach an undefined point.
Key takeaways
U.S. neffy net product rose 105% to $26.2 million, driven by higher unit sales volumes, and the product's share of the U.S. epinephrine market doubled to 5% overall and 8% in field-targeted accounts.
Selling, general and administrative expenses rose 43% to $77.6 million, including a $9.9 million increase in marketing-related expenses and $6.8 million in higher , $5.3 million of which came from accelerated vesting for a former executive.
Section summaries
Management's Discussion and Analysis
U.S. neffy net product revenue more than doubled YoY to $26.2M in Q2 2026, driving total revenue up 114%, while higher SG&A and interest expense widened the net loss to $62.3M.
⌄
Total grew 114% to $33.7M in Q2 2026, driven by a 105% increase in U.S. neffy net product revenue to $26.2M on higher unit sales volumes.
rose 158% to $12.8M, reflecting higher product costs from U.S. sales and global launches, plus increased royalty expenses on worldwide net product .
The net loss widened to $62.3 million from $44.9 million a year ago, as a $2.5 million from the and lower interest income turned other income into a net expense.
Cost of goods sold rose 158% to $12.8 million, reflecting higher product costs from U.S. sales and international launches, plus increased royalty expenses on worldwide net product .
Cash, cash equivalents, and short-term investments fell to $143.8 million from $240.1 million a year earlier, and management now expects existing resources plus additional term loan borrowings to fund operations only until is reached.
A securities class action lawsuit was filed in August 2026 alleging the company made material misstatements about the expected timeline for expanded insurance coverage for neffy.
What changed
The 'zero-cost' benefit flagged in Q2 2025 is winding down as expected; cost of goods sold rose 158% to $12.8 million, reflecting the shift to higher-cost inventory and increased royalty expenses.
The cash runway language has shifted further: after dropping the 'at least three years' phrasing in Q1 2026, management now states that existing cash plus additional term loan borrowings will fund operations to , without specifying when that point is expected.
The patent litigation landscape expanded: after Lupin's challenge in August 2025, Cipla has now also filed an ANDA with a Paragraph IV certification, and the company has initiated patent infringement lawsuits against both generic drugmakers.
A new risk emerged with the August 2026 securities class action lawsuit alleging material misstatements about the timeline for expanded insurance coverage, adding unplanned legal costs and management distraction to an already loss-making commercial ramp.
What to watch
Neffy U.S. net product in Q3 2026, to gauge whether the doubling of market share to 5% translates into a revenue trajectory that begins to close the gap against a quarterly SG&A run rate that reached $77.6 million.
The quarterly cash burn rate, to assess how quickly the $143.8 million reserve plus undrawn is being consumed now that management is targeting an undefined point.
Any ruling, settlement, or procedural development in the patent infringement lawsuits against Lupin and Cipla, which will determine how long neffy's market exclusivity lasts.
Interim data from the Phase 2b chronic spontaneous urticaria trial expected in the second half of 2026, which would indicate whether neffy can expand beyond its initial anaphylaxis indication.
Selling, general and administrative expenses increased 43% to $77.6M, primarily due to a $9.9M rise in marketing-related expenses and $6.8M in higher , including $5.3M from accelerated vesting for a former executive.
Net loss widened 39% to $62.3M, as a $2.5M from the new and lower interest income turned other income into a net expense.
Cash, equivalents, and short-term investments totaled $143.8M as of June 30, 2026; management believes existing resources and additional Term Loan borrowings are sufficient to reach .
U.S. epinephrine market share doubled to 5% overall and 8% in field-targeted accounts, with over 35,000 prescribers and approximately 167,000 patients prescribed neffy to date.
From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. See Note 9 – Commitments and Contingencies to the unaudited condensed consolidated financial statements in this Form 10-Q, which is incorporated by ref…
⌄
From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. See Note 9 – Commitments and Contingencies to the unaudited condensed consolidated financial statements in this Form 10-Q, which is incorporated by reference in this Part II, Item 1, for any required disclosure.
ARS Pharma's success depends entirely on neffy's commercial adoption, while generic patent challenges, pricing pressures, and operational scaling create material risks.
⌄
The company's near-term prospects are highly dependent on the successful U.S. and international commercialization of neffy, its only approved product, and any failure in market adoption by physicians, patients, or payors would materially harm the business.
Generic drugmakers Lupin and Cipla have filed ANDAs with paragraph IV certifications challenging patents on neffy, and ongoing litigation to block their market entry is expensive, time-consuming, and has an unpredictable outcome.
The company faces significant pricing and reimbursement risks, including potential application of a 'Most-Favored-Nation' pricing policy that could substantially reduce neffy's U.S. list price and market opportunity.
The company has incurred significant losses since inception, reporting a $123.0 million net loss for the six months ended June 30, 2026, and an of $417.6 million, and expects to continue incurring losses.
Rapid headcount growth from 23 to 195 full-time employees since July 2024 strains management and operational systems, creating risks in effectively managing the expansion of the commercial organization.
A securities class action lawsuit filed in August 2026 alleges the company made material misstatements about the expected timeline for expanded insurance coverage for neffy, the outcome of which is uncertain.